At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 158 enrolled
Drug / intervention
Galunisertib +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study of LY2157299 Monohydrate Monotherapy or LY2157299 Monohydrate Plus Lomustine Therapy Compared to Lomustine Monotherapy in Patients With Recurrent Glioblastoma
In Brief
A Phase 2 clinical trial evaluating Galunisertib, Lomustine, and 1 other intervention for Glioblastoma. Completed, enrolled 158 participants across 29 sites in 10 countries.
Detailed Summary
The purpose of the study is to see whether treatment with LY2157299 on its own, LY2157299 plus lomustine therapy or lomustine plus placebo can help participants with brain cancer
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlioblastoma
CountriesAustralia, Belgium, Canada, France, Germany, Italy, Netherlands, Poland, Spain, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedApr 2012
Enrollment StartApr 2012
Primary CompletionJul 2014
Study CompletionOct 2024
TodayJul 2026
First PostedApr 20, 2012
Enrollment StartApr 26, 2012
Primary CompletionJul 26, 2014
Study CompletionOct 10, 2024
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 14.2 years ago
Interventions
Galunisertibdrug
Administered orally
Lomustinedrug
Administered orally
Placebodrug
Administered orally